State Street
STRO icon

State Street’s Sutro Biopharma STRO Stock Holding History

State Street’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.3M Buy
52,118
+17,852
+52% +$323K ﹤0.01% 3426
2025
Q4 		$396K Buy
34,266
+1
+0% +$9 ﹤0.01% 3740
2025
Q3 		$298K Hold
34,265
– – ﹤0.01% 3791
2025
Q2 		$245K Sell
34,265
-133,969
-80% -$1.1M ﹤0.01% 3779
2025
Q1 		$1.09M Sell
168,234
-1,953
-1% -$30.8K ﹤0.01% 3408
2024
Q4 		$3.13M Buy
170,187
+5,471
+3% +$167K ﹤0.01% 3159
2024
Q3 		$5.7M Buy
164,716
+8,185
+5% +$321K ﹤0.01% 2901
2024
Q2 		$4.59M Buy
156,531
+36,859
+31% +$1.46M ﹤0.01% 2964
2024
Q1 		$6.76M Buy
119,672
+3,525
+3% +$156K ﹤0.01% 2796
2023
Q4 		$4.98M Buy
116,147
+5,568
+5% +$177K ﹤0.01% 2944
2023
Q3 		$3.84M Buy
110,579
+1,167
+1% +$50.8K ﹤0.01% 3049
2023
Q2 		$5.09M Sell
109,412
-182,859
-63% -$9.1M ﹤0.01% 2988
2023
Q1 		$13.5M Buy
292,271
+107,142
+58% +$6.8M ﹤0.01% 2482
2022
Q4 		$15M Buy
185,129
+102,340
+124% +$7.11M ﹤0.01% 2446
2022
Q3 		$4.59M Buy
82,789
+2,430
+3% +$144K ﹤0.01% 3102
2022
Q2 		$4.19M Sell
80,359
-183,890
-70% -$10.3M ﹤0.01% 3184
2022
Q1 		$21.7M Buy
264,249
+105,165
+66% +$10M ﹤0.01% 2333
2021
Q4 		$23.7M Sell
159,084
-11,151
-7% -$2M ﹤0.01% 2349
2021
Q3 		$32.2M Sell
170,235
-53,134
-24% -$10.1M ﹤0.01% 2136
2021
Q2 		$41.5M Sell
223,369
-28,047
-11% -$5.49M ﹤0.01% 1992
2021
Q1 		$57.2M Buy
251,416
+206,139
+455% +$48.9M ﹤0.01% 1643
2020
Q4 		$9.83M Buy
45,277
+12,877
+40% +$2.13M ﹤0.01% 2636
2020
Q3 		$3.26M Buy
32,400
+11,689
+56% +$1.1M ﹤0.01% 3001
2020
Q2 		$1.61M Buy
20,711
+2,850
+16% +$273K ﹤0.01% 3268
2020
Q1 		$1.82M Buy
17,861
+914
+5% +$96.1K ﹤0.01% 3102
2019
Q4 		$1.86M Buy
16,947
+1,363
+9% +$141K ﹤0.01% 3275
2019
Q3 		$1.42M Buy
15,584
+718
+5% +$72.5K ﹤0.01% 3326
2019
Q2 		$1.69M Buy
14,866
+6,129
+70% +$675K ﹤0.01% 3299
2019
Q1 		$995K Buy
8,737
+6,408
+275% +$667K ﹤0.01% 3340
2018
Q4 		$210K Buy
+2,329
New +$281K ﹤0.01% 3570

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street's STRO Position: Q1 2026 in Review

State Street increased its Sutro Biopharma (STRO) stake by 52% in Q1 2026, buying an estimated $323K and bringing the position to 52,118 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3426.

State Street first reported a position in STRO in Q4 2018 and has held it in 30 quarters since. The position peaked at $57.2M in Q1 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • State Street held 52,118 shares of Sutro Biopharma worth $1.3M as of Q1 2026.
  • State Street bought 17,852 Sutro Biopharma shares in Q1 2026, an estimated $323K.
  • Sutro Biopharma made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3426 holding.
  • State Street first reported a position in Sutro Biopharma in Q4 2018 and has held it in 30 quarters since.
  • State Street's Sutro Biopharma position peaked at $57.2M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.